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Abstract
To perform their regulatory functions, microRNAs (miRNAs) must assemble with any of the four mammalian Argonaute
(Ago) family of proteins, Ago1–4, into an effector complex known as the RNA-induced silencing complex (RISC). While
the mature miRNA guides the RISC complex to its target mRNA, the Ago protein represses mRNA translation. The
specific roles of the various Ago members in mediating miRNAs activity, however, haven’t been clearly established. In
this study, we investigated the contribution of Ago2, the only human Ago protein endowed with nuclease activity, to
the function of tumor-suppressor miR-145-5p in breast cancer (BC). We show that miR-145-5p and Ago2 protein are
concomitantly downregulated in BC tissues and that restoration of miR-145-5p expression in BC cells leads to Ago2
protein induction through the loosening of Ago2 mRNA translational repression. Functionally, miR-145-5p exerts its
inhibitory activity on cell migration only in presence of Ago2, while, upon Ago2 depletion, we observed increased
miR-145/Ago1 complex and enhanced cell motility. Profiling by microarray of miR-145-5p target mRNAs, in BC cells
depleted or not of Ago2, revealed that miR-145-5p drives Ago2-dependent and -independent activities. Our results
highlight that the Ago2 protein in cancer cells strictly dictates miR-145-5p tumor suppressor activity.
Introduction
MicroRNAs (miRNAs) are small non-coding RNAs able
to regulate gene expression at post-transcriptional level.
They control cell fate decision in several developmental
programs and their deregulation has been associated with
tumor progression1. It has been extensively demonstrated
that miRNAs may behave as oncogenes or tumor
suppressors; indeed, their altered expression during
tumorigenesis can promote or inhibit cancer progression.
MiRNAs are considered a relevant hallmark of cancer and
their clinical use to assess patient outcome, to monitor
progression and also for therapeutic purpose in cancer, is
rapidly emerging1.
To perform their regulatory functions, miRNAs must
assemble with any of the four mammalian Argonaute
(Ago) family of proteins, Ago1–4, into an effector com-
plex known as the RNA-induced silencing complex
(RISC)2. The miRNAs loaded in the RISC complex usually
function as negative regulators of gene expression, mainly
by targeting the 3’-untranslated region (UTR) of their
target mRNAs. In general, while the mature miRNA
guides the RISC complex to its target mRNA, the Ago
protein complex represses mRNA translation or induces
deadenylation-dependent mRNA decay, leading to
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silencing of gene expression2–4. Of note, despite a
remarkable homology that extends to the PIWI domains
among all four human Ago proteins, Argonaute2 (Ago2)
is the only human Ago protein endowed with nuclease
activity5–11.
As for miRNAs, also Ago2 deregulation has been linked
to cancer progression and treatment12–14. A number of
studies have shown Ago2 modulation also in breast car-
cinoma, providing contradictory results. For example
Kwon et al.15 and Blenkiron et al.16 showed, respectively,
down- and up-regulation of Ago2 mRNA in BC. With
concern to Ago2 function, Ago2 has been related to
miRNA-dependent tumor suppression as well as to pro-
tumoral functions, and the level of expression of specific
miRNAs may be an important determinant for Ago2
function17.
MiR-145-5p represents one of the miRNAs with
tumor suppressor function that is highly expressed in
normal tissues and downregulated in several human
cancers, including colorectal and breast cancer18. miR-
145-5p is located at chromosome 5q33.1 and is usually
transcribed in a bicistronic primary transcript with miR-
143. The epigenetic silencing of this region or the
deletion of this well known fragile site are common
events linked to cancer phenotype19–21. Of note, the
downregulation of miR-145-5p expression is associated
to the deregulation of several biological processes, such
as cell proliferation, cell migration, invasiveness, and
chemoresistance18–21. In lung cancer, for example, the
restoration of miR-145-5p expression reduces cell pro-
liferation and tumor growth targeting both EGFR and
NUDT122. miR-145-5p expression is consistently
downregulated also in prostate cancer, and its ectopic
expression in prostate cancer cells inhibits cancer cell
migration and invasion by targeting GOLM-1 (Golgi
membrane protein-1) mRNA23. GOLM-1 protein
expression has been reported to be highly upregulated in
cancer tissues and high GOLM-1 expression has been
related to poor outcome. In breast cancer, miR-145-5p
is strongly downregulated in cancer tissues compared to
normal samples24. Interestingly, the expression of this
miRNA has been found to inversely correlate with the
expression of two proteins, JAM-A and FASCIN, in
breast cancer cell lines25. Restoration of miR-145-5p
expression in MDA-MB-231, MCF-7, MDA-MB-468
breast cancer cell lines resulted in strong reduction of
cell motility and invasion, demonstrating the important
role of this miRNA in suppressing tumor dissemina-
tion25. miR-145-5p also impacts on drug response,
by post-transcriptional regulation of specific
pharmacogenomic-related genes, as MRP1 (multidrug
resistance (MDR)-associated protein 1, also known as
ABCC1), the most important human ABC transporter
involved in drug disposition and in multi-drug
resistance (MDR)26. The contribution of miR-145-5p to
tumor initiation and progression is however still deba-
ted as this miRNA has been recently described also as a
non-cell autonomous oncogenic factor rather than a
tumor suppressor27. We wondered whether Ago2
activity influenced the tumor suppressor/oncogenic
function of miR-145-5p in breast cancer cells. We also
explored if decreased Ago2 level favored the formation
of alternative complexes with other Argonaute family
members.
Results
miR-145-5p specifically upregulates Ago2 expression
As mentioned, downregulation of tumor suppressor
miR-145-5p is a frequent event in human tumors, inclu-
ded breast cancer, and leads to the increased expression of
its target mRNAs. For example, Thymic Epithelial
Tumors show downregulated miR-145-5p and increased
expression of its motility-related target genes Golm-1,
EGFR and CDH2; moreover, in breast cancer miR-145
exogenous expression was shown to promote the inhibi-
tion of cell growth and the induction of apoptosis by
targeting the Rho-effector rhotekin (RTKN)18,21. Also
Ago2, crucial mediator of miRNAs activity, has been
reported to be modulated in breast cancer15, despite
contradictory results have been obtained regarding the
kind of modulation (up- or down-regulated depending on
the considered study) and the functional output of such
modulation.
Aiming to investigate the contribution of Ago2 to miR-
145-5p function in breast cancer, we first evaluated their
expression in BC tissues. We confirmed that miR-145-5p
expression is reduced in breast cancer compared to nor-
mal tissues in the TGCA breast cancer dataset (Fig. 1a)
and in a small group of matched FFPE (Formalin-Fixed,
Paraffin-Embedded) primary triple-negative BC and nor-
mal adjacent tissues (Fig. 1b).
Using this small group of tumors and normal adjacent
counterparts we then evaluated by IHC the expression of
Ago2 protein. We observed that miR-145-5p down-
regulation was accompanied by a reduction also of Ago2
protein level in tumor tissues compared to the normal
counterparts (Fig. 1c, d). In normal tissues, presenting
organized tissue morphology, Ago2 mainly localized in
the epithelial cells of glandular ducts (Fig. 1c, d).
On the basis of the downregulation observed for both
miR-145-5p and Ago2 in BC, we moved to breast cancer
cell lines, to evaluate whether modulation of miR-145-5p
levels had any effect on Ago2 expression. Ago2 protein
levels have been indeed reported to depend on miRNAs
overall expression28,29. Ectopic expression of miR-145-5p
in a panel of breast cancer cell lines (MDA-MB-231,
MCF7, SKBR3, MDA-MB-468) induced a consistent
increase of Ago2 protein, compared to control miRNA
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(CTR) (Fig. 2a, b). Interestingly, a similar effect was also
observed in additional non-breast carcinoma cell lines
(Fig. 2a, b). Differently from what observed for Ago2, we
did not observe a pervasive modulation of Ago1 protein in
the analyzed cell lines (Fig. 2a–c).
Analysis of mRNA levels evidenced that miR-145-5p
doesn’t affect Ago1 nor Ago2 mRNA expression (Sup-
plementary Figure 1A–B), except in the MDA-MB-231
cell line where Ago2 transcript is induced (Supplementary
Figure 1A). These results suggest that miR-145-5p could
affect Ago2 expression mainly through post-
transcriptional mechanisms.
In agreement, the transfection of miR-145-5p inhibitor
oligonucleotide in Hs578T breast cancer cells, expressing
high level of miR-145-5p (Supplementary Figure 1C), led
to a decrease of Ago2 protein level compared to control
inhibitor (Supplementary Figure 1D–E).
To further confirm the specificity of the effect observed
on Ago2 protein levels, we evaluated the ability of miR-
145-5p inhibitor oligonucleotide to counteract miR-145-
5p-dependent Ago2 induction. As shown in Fig. 2d,
Western blot and relative densitometry evidenced that
miR-145-5p inhibitor oligonucleotide impaired the ability
of miR-145-5p to induce Ago2 expression.
Fig. 1 The loss of Ago2 expression correlates with miR-145-5p downregulation in breast cancer FFPE tumor samples. a Box plot showing
the miR-145-5p expression in the various intrinsic subtypes of breast cancer tissues relative to normal tissues by using TGCA data; Clinical information
of breast cancer patients and normalized TCGA miRNAseq data were obtained from http://gdac.broadinstitute.org/ (doi. 10.7908/C11G0KM9) and
from Genomic Data Commons Data Portal (https://cancergenome.nih.gov/). Deregulation among different subgroups of samples was assessed by
one way Anova test and two-sided t-test. b Box plot showing the modulation of miR-145-5p expression in 11 matched triple negative tumor tissues
vs normal samples; c, d Immunohistochemistry for Ago2 in slides from 2 representative patients (Pt) with relative scale bars
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To evaluate if any miRNA caused Ago2 induction, we
transfected MDA-MB-231 cells with a panel of mimic
miRNAs (miR-145, miR-128, miR-223, and miR-10b*)
and the relative controls. By Western blot we evidenced
that only miR-145-5p and miR-10b* were able to upre-
gulate of Ago2 expression (Fig. 2e), suggesting the exis-
tence of specific miRNA-dependent modulation of Ago2
expression.
miR-145-5p enhances Ago2 mRNA translation
Ago2 mRNA itself has been shown to undergo miRNA-
dependent translational repression30,31. To clarify the
molecular mechanisms supporting the miR-145-5p-
dependent Ago2 protein induction, we first evaluated
the interaction of Ago2 mRNA with Ago1 and Ago2
proteins, important components of the post-
transcriptional control machinery. Immunoprecipitations
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Fig. 2 miR-145-5p regulates Ago2 expression. a Western blot analysis of Ago2 and Ago1 proteins from whole cell lysates of MDA-MB-231, MCF7,
SKBR3, MDA-MB-468, H1299, A459 and TC1889, after 48 h of miR-145-5p ectopic expression; b, c Graphs representing Ago2 (b) and Ago1 (c) protein
expression obtained by densitometry of Western blots shown in a and normalized over tubulin signals; analysis of MDA-MB-231 (right graphs) derives
from three biological replicates. P-values were calculated by two-tailed t-test. dWestern blot analysis of Ago2 protein from whole cell lysates of MDA-
MB-231 transfected for 48 h with miR-145-5p or the relative control mimic, the inhibitor of miR-145-5p (INH-145) or negative control (INH-C) or
transfected with both the control mimic and the negative inhibitor (CTR+ INH-C) or both miR-145-5p and the inhibitor of miR-145-5p (INH-145);
histogram (right) shows the densitometric analysis of Ago2 levels relative to Tubulin expression; data are presented as mean ± SEM from two
biological replicates. e Western blot image (left) and densitometric analysis (right) of Ago2 protein after 48 h of miR-145-5p, miR-128, miR-223, miR-
10b* overexpression; data are presented as mean ± EM from two biological replicates
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of Ago2 and Ago1 proteins followed by RT-qPCR for
Ago2 mRNA (RIP assay) showed that Ago2 transcript
interacts with both proteins in MDA-MB-231 cells
(Fig. 3a, b). Interestingly, ectopic expression of miR-145-
5p reduces the interaction of Ago2 mRNA with Ago2 and
Ago1 proteins (Fig. 3a, b), suggesting a loosening of the
miRNA-dependent negative control of Ago2 mRNA
expression.
We next evaluated the abundance of Ago2 mRNA in
cellular fractions of different ribosomal density. We
observed that miR-145-5p transfection resulted in a shift
of Ago2 mRNAs from low- to high-density ribosomal
fractions, indicating increased translation (Fig. 3c). Alto-
gether these results are in agreement with a release of the
translational repression leading to Ago2 protein induction
following miR-145-5p expression.
miR-145-5p inhibits migration in Ago2-dependent manner
To investigate the functional output of miR-145-5p-
Ago2 axis, we decided to evaluate its impact on cell
migration, a function controlled by miR-145-5p in breast
cancer cells25,32.
To this end, we first checked if miR-145-5p ectopic
expression in MDA-MB-231 cells recapitulated the major
functions previously reported for this miRNA in breast
cancer cells. Specifically, we confirmed that miR-145-5p
induced a significant downregulation of its targets Jam-A
and Golm-1 (Supplementary Figure 2A–C), implicated in
cell migration control. Accordingly, the migration ability
of MDA-MB-231 cells overexpressing miR-145-5p was
reduced compared to control (Supplementary Figure 2D).
On the contrary, cell cycle progression was not affected by
miR-145-5p expression (Supplementary Figure 2E) at
least at the analyzed time point.
We then evaluated the impact of Ago2 modulation on
MDA-MB-231 cell motility. Enforced expression of Ago2
has been reported to sustain cell motility in MCF-7 cells33.
We observed that ectopic expression of Ago2 increased
the migratory ability also of MDA-MB-231 cells (Sup-
plementary Figure 3A), while Ago2 silencing consistently
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Fig. 3 miR-145-5p enhances Ago2 mRNA translation. a, b RIP (RNA Immuno Precipitation) assays performed in control (CTR) and miR-145-5p
overexpressing (145-5p) MDA-MB-231 cells using antibodies directed to Ago2, Ago1, or IgG as negative control. mRNA abundance of Ago2 was
evaluated by RT-qPCR and normalized over GAPDH mRNA; a representative experiment of a biological duplicate is shown. c Cytoplasmic extracts
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correlated with decreased migration capacity of cells
(Supplementary Figure 3B).
Finally, we investigated the impact of miR-145-5p
overexpression on cell migration of cells depleted or not
of Ago2 expression. As expected, miR-145-5p over-
expression inhibited migration in control MDA-MB-231
and MDA-MB-468 cells (SCR) (Fig. 4a–d). Migration was
reduced to a similar extent after Ago2 silencing (siAgo2)
(Fig. 4a–d). Interestingly, miR-145-5p overexpression in
Ago2-depleted cells did not induce further reduction of
migration but, on the contrary, enabled recovery of
migration ability (Fig. 4a–d).
These results indicate that miR-145-5p elicits its inhi-
bitory effect on migration only in presence of Ago2
expression, while, in the absence of Ago2 protein, it exerts
an opposite pro-migratory function.
The absence of Ago2 enhances to the formation of miR-
145-5p/Ago1 alternative active complex
To investigate if, in the absence of Ago2, a potentiation
of the alternative miR-145-5p/Ago1 active complex is
observed, we performed RNA immunoprecipitation (RIP)
assays. To this end, MDA-MB-231 cells overexpressing
miR-145-5p, depleted (siAgo2-145-5p) or not (scr-145-
5p) of Ago2 expression, were used to perform
immunoprecipitations with anti-Ago1 antibody or IgG as
control. As shown in Fig. 5a, b, we observed increased
miR-145-5p/Ago1 interaction in cells depleted of Ago2,
compared to si-SCR cells, while no change for RNU6B/
Ago1 interaction was observed. These results indicate that
when Ago2 is depleted, miR-145-5p specifically increases
its interaction with Ago1 protein. On this basis, we
wondered if Ago1 protein might change its subcellular
localization upon Ago2 depletion. As shown in Supple-
mentary Figure 4, neither miR-145-5p ectopic expression
nor Ago2 depletion altered the localization of Ago1 or
Ago2 proteins, which are mostly cytoplasmatic. Based on
these results, it is possible to speculate that miR-145-5p
behaves as a tumor suppressor miRNA when it is com-
plexed with Ago2 protein, while miR-145-5p activity may
become oncogenic in the absence of Ago2, through the
interaction with other RNA-binding proteins (RBPs), as
for example Ago1.
miR-145-5p exerts Ago2-dependent and -independent
activities
To evaluate the impact of miR-145-5p on global gene
expression, in presence or absence of Ago2 protein, we
performed gene expression profiling in MDA-MB-231
cells, overexpressing or not miR-145-5p and depleted or
control miR-145-5p 
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not of Ago2 expression, as described in the two previous
paragraphs. Microarray analysis revealed that miR-145-5p
expression leads to the modulation of 1538 transcripts, of
which 698 downregulated and 840 upregulated (Supple-
mentary Figure 5 and Supplementary File 1). Among the
downregulated mRNAs, potential direct targets of miR-
145-5p, we found genes controlling cell proliferation (as
for example CCNG1, CDK6, MAP3K1, MAP3K8,
MAP3K4), cell motility (as PCDH1, GOLM1, JAM-A and
various members of RAB family of proteins) and che-
moresistance (as the five members of ATP-binding cas-
sette transporters ABCA1, ABCA11P, ABCB10, ABCD4
and ABCE1). Thirty-five of the downregulated genes were
previously identified and validated as direct targets of
miR-145-5p as indicated by the miRTarBase data reposi-
tory34 (Supplementary File 2).
Of note, we observed that, in the absence of Ago2
expression, miR-145-5p loses the ability to control 86% of
its modulated transcripts, while retains 14% of its func-
tions (Fig. 6a–b). Pathway and Gene Ontology analyses
reporting the functions of the genes controlled by miR-
145-5p, retained or not upon depletion of Ago2, is shown
in Supplementary File 3.
Interestingly, we observed that miR-145-5p gains new
functions in the absence of Ago2, acquiring the ability to
modulate the expression of a different panel of genes (118
down- and 414 up-regulated transcripts), possibly
through the formation of complexes with other RBP, as
for example Ago1, at least for the downregulated targets
(Fig. 6b). Pathway and Gene Ontology analyses revealed
that different functions are exerted by miR-145-5p in
absence of Ago2 compared to control cells (Supplemen-
tary File 3). Interestingly, different sets of cell adhesion
molecules (CAMs) are modulated by miR-145-5p in
presence or in absence of Ago2; this might reflect the
opposite effect on cell motility observed upon miR-145-5p
exogenous expression in these two conditions (as shown
in Fig. 4a).
Based on our results, miR-145-5p is supposed to
exert its tumor suppressor function only in presence of
Ago2 expression; we then reasoned that the Ago2-
dependent transcripts modulated by miR-145-5p in
MDA-MB-231 cells could mediate tumor suppressor
function and may represent predictive indicators in
breast cancer. To test this, we first selected a few genes
among the most significantly downregulated by miR-
145-5p in presence of Ago2, we validated their mod-
ulation (Figure 6c) and we evaluated their predictive
power using various breast cancer cohorts. Specifically,
we observed that low expression of a signature com-
prising the top 5 downregulated genes (DECR1, GFM2,
DOCK9, VDAC3 and ETFB) (P < 0.0005) associates with
increased overall survival in patients from a compen-
dium of breast cancer studies (N= 626) included in the
KMplot database (Fig. 6d)35. A similar result was
observed evaluating the Metabric and the TCGA
cohorts for overall and disease-free survival, respectively
(Supplementary Figure 6). Opposite behavior was
observed for miR-145-5p expression, whose high levels
associate with higher survival probability (Fig. 6e); this
result is specific for lymph node-negative patients,
indicating that deregulation of miR-145-5p expression
might be relevant for the initial stages of breast
carcinogenesis.
Analysis of TCGA and Metabric cohorts enabled also to
assess that various couples of these genes present co-
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occurring overexpression in breast cancer (Figure 6f and
Supplementary Figure 6D).
Overall these results indicate that miR-145-5p exerts its
tumor suppressor function in cells expressing Ago2 pro-
tein and suggest that Ago2 protein might contribute to
the choice of targets by miR-145-5p.
Discussion
Our study shows that both miR-145-5p and Ago2
protein are downregulated in breast cancer. Results about
miR-145-5p are in line with report by Sempere and col-
leagues36, showing that expression of miR-145-5p is
reduced or even completely abrogated in breast tumors.
Fig. 6 miR-145-5p exerts Ago2-dependent and -independent activities. a Expression matrix of transcripts whose expression is modulated by
miR-145-5p in Ago2-dependent manner. b Diagrams showing the number of transcripts downregulated (upper panel) and up-regulated (lower
panel) by miR-145-5p in presence (si-CTR) and in absence (si-Ago2) of Ago2 expression. c Validation by RT-qPCR of the expression of 5 top modulated
miR-145-5p-dependent genes in the indicated experimental conditions, performed on three biological replicates. d Kaplan–Meier analysis of overall
survival has been performed on a compendium of breast cancer microarray datasets deposited in the KMplot database, using a signature comprising
the 5 transcripts most strongly modulated by miR-145-5p. e Kaplan–Meier analysis of overall survival has been performed on the Metabric cohort of
breast cancer evaluating miR-145-5p expression levels. f Co-occurrence analysis of the overexpression of the 5 genes most strongly modulated by
miR-145-5p in the Metabric breast cancer cohort performed using the cBioPortal cancer genomics database
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Moreover, we show that miR-145-5p specifically indu-
ces post-transcriptionally Ago2 protein expression in both
breast and non-breast carcinoma cell lines. This is
obtained possibly through the loosening of Ago2 trans-
lational repression following miR-145-5p overexpression.
Induction of Ago2 protein is necessary to allow miR-145-
5p tumor suppressor function. In absence of Ago2 indeed
miR-145-5p-dependent inhibition of migration is not
observed while, on the contrary, we observed an
enhancement of migration. At molecular level, upon Ago2
depletion an increase of miR-145-5p/Ago1 complex is
observed. This suggests that when Ago2 is downregulated
miR-145-5p might be involved in interactions with addi-
tional RNA-binding proteins (RBPs), as Ago1 for example,
and acquire different functions. This is also reflected by
the microarray analysis in cells overexpressing miR-145-
5p. We indeed observed that most of miR-145-5p func-
tions are lost upon Ago2 depletion, while additional
functions are gained. miR-145-5p indeed leads to the
modulation of a huge number of genes in the absence of
Ago2, genes whose modulation is not observed in the
presence of Ago2 expression. We can hypothesize that
these genes may depend on the activity of miR-145-5p
complexed with other members of Ago family of proteins
or additional RNA-binding proteins. Further studies will
enable clarifying the functional output of the modulation
of this Ago2-independent set of genes. However, as
restoration of tumor suppressor miRNA levels has been
proposed recently as a promising therapeutic intervention
to cure diverse cancers, our study underlines how infor-
mation about Ago2 protein expression level becomes
crucial for the success of these novel therapeutic
approaches. Moreover, Ago2 protein activity and stability
are controlled by post-translational modifications, as for
example phosphorylation at Tyr 393;37 possibly, these
Ago2 post-translational modifications might contribute to
the definition of miRNA-specific target recognition and,
consequently, determine the biological output of tumor
suppressor and oncogenic miRNAs.
Conclusions
In summary, our results show that miR-145-5p depen-
dent tumor suppressor function is exerted only in pre-
sence of Ago2 protein expression. Our findings suggest
that Ago2 downregulation in breast cancer might strongly
influence the activity of miRNAs and highlight the
importance of evaluating Ago proteins levels when
studying miRNAs activity in cancer.
Materials and methods
Cell culture and transfection
MDA-MB-231, SKBR3, MDA-MB-468, H1299, A459
cell lines were cultured in DMEM medium supplemented
with 50 U/mL penicillin, 50 U/ml streptomycin and 10%
heat-inactivated FBS at 37 °C in an incubator with
humidified 5% CO2 atmosphere. Human Thymic Carci-
noma cell line TC1889 was kindle provided by Dott. M
Breining38 and cultured in RPMI 1640 containing 4.5 g/L
glucose, 25 mM Hepes, 50 U/mL penicillin, 50 U/ml
streptomycin and 10% heat-inactivated FBS at 37 °C in an
incubator with humidified 5% CO2 atmosphere. Hs578T
was cultured in DMEM with 0.01 mg/mL human insulin
with a fetal bovine serum to a final concentration of 10%.
MCF10A was cultured in F12 medium supplemented with
5% horse serum, 10 ug/mL Insulin, 0.5 ug/mL Hydro-
cortisone and 20 ng/mL EGF.
Pre-miR-145-5p (PM11480 #AM17100, Ambion), Pre-
miR-223 (PM12672 #AM17100, Ambion), Pre-miR-10b*
(PM12387, #AM17100 Ambion), Pre-miR-128 (PM24586
#AM17100, Ambion) and Pre-miRNA Negative Control
(#AM17110, Ambion) were transfected at final con-
centration of 5 nM using Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s instructions.
For gene silencing experiments, MDA-MB-231 were
transfected with Dicer-substrate short interfering RNAs
(DsiRNAs) for AGO2 (IDT, Belgium) and NC1 negative
control (IDT, Belgium) at 500 pM for 72 h.
For the inhibition of miRNA expression, MDA-MB-231
cells were transfected with hsa-miR-145-5p mirVana
miRNA inhibitor (#MH11480, Ambion) and negative
control #1 (#4464077, Ambion) at final concentration of
5 nM using Lipofectamine RNAiMAX (Invitrogen)
according to the manufacturer’s instructions.
For Ago2-HA exogenous expression, MDA-MB-231
cell line was transfected with Ago2-HA vector provided
by Prof. Filipowicz39 by using Lipofectamine 2000 (Invi-
trogen), according to the manufacturer’s instructions.
Total RNA extraction from cells and reverse transcription
Total RNA was extracted using the TRIZOL Reagent
(GIBCO). 500 ng of total RNA were reverse-transcribed
using High-Capacity RNA-to-cDNA Kit (Applied Bio-
systems) and diluted 1:5 for PCR reactions. PCR analyses
were carried out by using oligonucleotides specific for the
genes listed in Supplementary Table 1 and gene expres-
sion was measured by real-time PCR using the Sybr Green
assay (Applied Biosystems, Carlsbad, CA, USA) on Abi
Prism 7500 (Applied Biosystems). All reactions were
performed in duplicate.
RNA from FFPE samples was extracted using the
miRneasy FFPE kit (Qiagen, Chatsworth, CA) following
the manufacturer’s instructions. 50 ng of total RNA was
reverse transcribed in 20 μl by using miScript II RT kit
(Qiagen, Chatsworth, CA) and 1 μl of cDNA dilution (1:5)
was used for quantitative real-time PCR (RT-qPCR)
experiments. Quantification of miR-145-5p was carried
out by miScript Primer Assay (Hs_miR-145_1 miScript
Primer Assay MS00003528 Qiagen, Chatsworth, CA),
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normalizing over RNU6B control (Hs_RNU6-2_11 miS-
cript Primer Assay MS00033740 Qiagen, Chatsworth, CA)
and using the miScript SYBR Green PCR kit (Qiagen,
Chatsworth, CA) on Abi Prism 7500 (Applied Biosys-
tems). All reactions were performed in duplicate.
Lysate preparation and immunoblotting analysis
Cells were lysed in 2% SDS buffer (25 mM Tris-Hcl pH
7.5, 100mM Nacl, 3 mM EDTA, 7% Glycerol) and fresh
protease inhibitors. Extracts were sonicated for 10 s and
centrifuged at 12,000 × rpm for 10min to remove cell
debris. Western blotting was performed using the fol-
lowing primary antibodies: mouse monoclonal anti-
Gapdh 6C5 (#sc32233, Santa Cruz Biotechnology);
mouse monoclonal anti-Tubulin B512 (#T5168, Sigma-
Aldrich, Milan, Italy); mouse monoclonal anti-b-Actin
(ACTBD11B7) (Santa Cruz Biotechnology sc-81178),
rabbit polyclonal anti-Golm1 (#PA5-30622, Thermo Sci-
entific); rabbit polyclonal antibodies: anti-Ago2 (#2897,
Cell Signaling); rabbit monoclonal antibodies anti-Ago1
(D84G10) XP (#5053, Cell Signaling); rabbit monoclonal
antibodies anti HA-Tag (#3724, Cell Signaling).
As secondary antibodies goat anti-mouse and anti-
rabbit conjugated to horseradish peroxidase were used
(Bethyl Laboratories). Western blot analysis was per-
formed with the aid of the enhanced chemiluminescence
system (Thermo Fisher Scientific, Rockford, IL, USA).
ECL detection was done using a ChemiDoc-It Imaging
System (UVP, Upland, CA) instrument.
Nuclear and cytoplasmic extracts preparation
Cells were lysed in hypotonic buffer (50 mM HEPES;
150mM NaCl; 2 mM EDTA; 10mM MgCl2, 10 mM KCL;
0.5% Nonidet P-40; fresh DTT 2.5 mM and fresh protease
inhibitors) for 15 min on ice followed by 5min of cen-
trifugation at 1200 rpm. The supernatants were removed
and used as cytosolic fraction and the pellet (corre-
sponding to the nuclei) was resuspended in 2% SDS buffer
(25 mM Tris-Hcl pH 7.5, 100 mM NaCl, 3 mM EDTA, 7%
Glycerol) and fresh protease inhibitors. Extracts were
sonicated for 10 s and centrifuged at 12,000 × rpm for 10
min to remove cell debris and to obtain nuclear proteins.
Mouse anti-Gapdh 6C5 (#sc32233, Santa Cruz Bio-
technology) and rabbit polyclonal anti Histone H3
(#Abcam 1791) were used as markers of the cytoplasmic
and nuclear fraction, respectively.
Cell cycle analysis
For cell cycle analysis, 2 × 105 cells were resuspended in
50% FCS, fixed in 70% ethanol for 24 h, incubated with 50
μg/ml propidium iodide (Sigma-Aldrich) and 50 units/ml
Dnase-free RNase A (Sigma-Aldrich) and analyzed after 3
h (1 × 104 events) using an Epics XL Cytometer (Beckman
Coulter).
Transwell migration assay
Migration assay was performed by using a 24-well
plate with a non-coated 8-mm pore size filter in the
insert chamber (BD Falcon, Franklin Lakes, NJ, USA).
MDA-MB-231 or MDA-MB-468 cell lines were trans-
fected with pre-miR-145-5p and the pre-miRNA Pre-
cursor-Negative Control (Ambion) for 48 h or silenced
with siAgo2 or NC1 negative control (IDT, Belgium) at
500 pMoles or transfected with pcDNA3-Ago2-HA or
pcDNA3-HA vectors for 72 h. After transfection, 5 × 104
cells were resuspended in serum-free DMEM and see-
ded into the insert chamber. Cells were allowed to
migrate for 24 h into the bottom chamber containing
0,7 ml of DMEM supplemented with EGF (30 ng/ml) in
a humidified incubator at 37 °C in 5% CO2. Cell
migration was evaluated by discarding cells which did
not migrate (upper side) and by counting the number of
cells on the underside of the membrane using DAPI
staining.
Immunohistochemistry
Ago2 protein expression was analyzed by immunohis-
tochemistry (IHC) in a set of 11 triple negative FFPE
breast tumors and 11 normal counterparts from patients
who underwent surgery from 2014 to 2015 (Sapienza
University of Rome, Pathology Unit, ICOT, Latina, Italy)
and summarized in the Supplementary Table 2. None of
the patients had received any radio or radio-
chemotherapy before surgery. Formalin-fixed, paraffin-
embedded 5μm sections were Haematoxylin and Eosin
stained to select well-represented epithelial cell com-
partment. Serial/subsequent sections were stained with
the anti-Ago2 antibody (#ab57113, Abcam) at 1:100
dilution. Protein staining was revealed through DAB
enzymatic reaction while nuclei were counterstained with
hematoxylin.
Polysome profiling
After 48 h of transfection with Pre-miR-145-5p
(PM11480 #AM17100, Ambion) and Pre-miRNA Pre-
cursor Negative Control (#AM17110, Ambion), 20 × 106
cells were lysed with 400 μl of lysis buffer (10 mM Tris pH
7.5, 10 mM NaCl, 10 mM MgCl2, 1% Triton X-100) sup-
plemented with 10mM fresh DTT, 100 μg/ml cyclohex-
imide, 1X PIC (Complete, EDTA free, Roche) and 1X
RNase guard (Thermo Scientific).
Cells were allowed to swell for 10 min on ice. The
lysates were centrifuged for 10min at 13,000 rpm at 4 °C.
The supernatants were collected and centrifuged on
15–50% sucrose gradient at 38,000 rpm with a SW41
rotor (Beckman) for 1 h 30min at 4 °C. Fractions were
collected with a Bio-logic LP (Biorad). Total RNA derived
from 300 μl of fraction was extracted using 700 μl of
TRIZOL Reagents (GIBCO).
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RNA-binding protein immunoprecipitation (RIP) assay
Lysates from 20 × 106 cells were immunoprecipitated
using the Magna RIP kit (#17-700, Millipore) following
the manufacturer’s instructions with an anti-Ago2 anti-
body (Millipore, # 03-110) and anti-Ago1 antibody (Mil-
lipore #03-249) or control IgG.
Binding of miRNAs and Ago2 mRNA respectively to
Ago1 or Ago2 was evaluated by RT-qPCR. The quantifi-
cation of miR-145-5p or RNU6B or Ago2 mRNA was
carried out on Abi Prism 7500 (Applied Biosystems) using
the miScript SYBR Green PCR kit (Qiagen, Chatsworth,
CA) and all the reactions were performed in duplicate.
Microarray analysis
Expression profiling by microarray has been performed
on the Agilent platform using Low Input Quick Amp WT
Labeling Kit, one-color, on SurePrint G3 Human Exon
2 × 400 K slides. Gene expression profiling from Agilent
arrays was extracted by Agilent Feature Extraction soft-
ware. Values lower than 1 were considered below detec-
tion and thresholded to 1. Signals were quantile
normalized and log2-transformed. Gene modulation was
assessed using a permutation test and a paired T-test. A
false discovery procedure was also included for multiple
comparisons. Unsupervised hierarchical clustering was
performed by using the Euclidean distance metric.
Bioinformatic analyses were performed by MATLAB
(The MathWorks). Pathway and Gene Ontology analyses
were performed using the DAVID functional annotation
tool (https://david.ncifcrf.gov). Microarray data are avail-
able as GSE120896 in GEO Database (https://www.ncbi.
nlm.nih.gov/geo).
Survival analyses
Survival analyses were performed on the KMplot data-
base35 using as input the 6-genes signature of miR-145-5p
top downregulated genes on the whole breast cancer
dataset (N= 626). Logrank P and HR were calculated
using GraphPad Prism 7 software. Survival analyses on
the Metabric and TCGA cohorts were performed using
the cBioPortal Database (http://www.cbioportal.org) using
as input the mRNA expression levels of the 6-genes
signature.
Statistical analyses
The statistical analyses were performed using GraphPad
Prism 7 (GraphPad Software, San Diego California USA).
Values of P ≤ 0.05 (*) and P ≤ 0.01 (**) were considered
statistically significant.
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